Author:
Uzelac Ilija,Iravanian Shahriar,Ashikaga Hiroshi,Bhatia Neal K.,Herndon Conner,Kaboudian Abouzar,Gumbart James C.,Cherry Elizabeth M.,Fenton Flavio H.
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference30 articles.
1. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro;Liu;Cell Discov,2020
2. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Published online March 9, 2020. Clin Infect Dis https://doi.org/10.1093/cid/ciaa237.
3. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Published online March 20, 2020. Int J Antimicrob Agents https://doi.org/10.1016/j.ijantimicag.2020.105949.
4. Statement on IJAA Paper. Official Statement from International Society of Antimicrobial Chemotherapy. Available at: https://www.isac.world/news-and-publications/official-isac-statement.
5. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19];Chen;Zhejiang Da Xue Xue Bao Yi Xue Ban,2020
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献